Pharmaceuticals & Biotech

ZS portfolio and business development quarterly: Q1 2024

April 30, 2024 | Research Report | 7-minute read

ZS portfolio and business development quarterly: Q1 2024


Our first ZS portfolio and business development quarterly webinar of the year offered key insights for pharma leaders executing their 2024 strategies. This report, based on that same data, highlights:

  • New drug success: Launches and revenue generated by new molecular entities approved in 2023
  • Industry growth drivers: Which types of organizations are fueling the industry’s overall valuation increase
  • Funding innovation: New funding avenues pharmaceutical companies are exploring
  • Clinical trial trends: The reasons behind the decline in clinical trial volume
  • Investment hotspots: Therapeutic areas attracting the most deal activity

Complete this form to stay in the loop.

Add insights to your inbox

We’ll send you content you’ll want to read – and put to use.





About the author(s)